On Monday, the Food and Drug Administration announced it would no longer permit the use of two monoclonal antibody treatments for the treatment of COVID-19. Prior to this announcement, one treatment used Bamlanivimab and Etesevimab (used together) and the Regeneron treatment, which was a combination of Casirivimad and Imdevimab.

